LifeStance Health Group, Inc. 8-K

What Happened LifeStance Health Group, Inc. filed an 8‑K on February 25, 2026 announcing its results of operations for the fourth quarter and full year ended December 31, 2025 (press release furnished as Exhibit 99.1) and furnishing a supplemental slide presentation (Exhibit 99.2). On February 24, 2026 the Board approved a share repurchase program authorizing up to $100 million in repurchases. Also on February 25, 2026, Executive Chairman Kenneth Burdick announced he will transition to non‑executive Chairman effective March 16, 2026; this change is not due to any disagreement with management or the Board.

Key Details

• The 8‑K was filed Feb 25, 2026 and includes a press release (Exhibit 99.1) and a slide presentation (Exhibit 99.2) with supplemental financial information.
• The Board authorized a repurchase program of up to $100 million of common stock; repurchases are discretionary and may be made in open market or privately negotiated transactions.
• Kenneth Burdick will become non‑executive Chair on March 16, 2026 and will receive an annual cash retainer of $200,000 plus an annual grant of RSUs with a grant‑date fair market value of approximately $500,000.
• The filing was signed by Ryan McGroarty, Chief Financial Officer and Treasurer.

Why It Matters This 8‑K signals three investor‑relevant actions: LifeStance publicly released its quarterly and full‑year financial results (investors should review the attached press release and slides for revenue and earnings details), the Board authorized a sizable $100M buyback program that could support the stock and reduce shares outstanding over time, and the company is changing its board leadership structure with the Executive Chairman moving to a non‑executive role (with disclosed compensation). None of these items indicate any disagreement with management; for detailed financial figures, refer to Exhibit 99.1 and the slide deck (Exhibit 99.2).